Wed, Apr 16, 2014, 8:17 PM EDT - U.S. Markets closed


% | $
Quotes you view appear here for quick access.

Exelixis, Inc. Message Board

conditionstabel 7 posts  |  Last Activity: Mar 25, 2014 9:38 AM Member since: Aug 23, 2012
SortNewest  |  Oldest  |  Highest Rated Expand all messages
  • Reply to

    Mother of All Short Squeezes

    by icprecipice Mar 25, 2014 9:07 AM
    conditionstabel conditionstabel Mar 25, 2014 9:38 AM Flag

    Every one of these major shorts is
    hedged with the Convertible bonds and so i don't see any short squeeze coming until there is an interim Comet 1 positive indication which would put us back above the 6.90 level for along enough period to have EXEL force conversion.

  • Reply to

    BMY on the prowl!

    by enabeler Jan 26, 2014 12:44 PM
    conditionstabel conditionstabel Jan 26, 2014 1:07 PM Flag

    "Actually, $.8 Bil"; sorry should read "$4.8Bil".

  • Reply to

    will this cause shorts to cover

    by mj525252 Jan 6, 2014 8:42 AM
    conditionstabel conditionstabel Jan 6, 2014 9:03 AM Flag

    The hedge fund shorts and the non hedged shorts will do everything in their power to keep the genie in the bottle. Short covering may not become an issue until we trade above 6.90 for a 20 out of a 30 day period. The hedge would no longer work in their favor and conversion would make sense as they deliver their new shares to cover the short, and EXEL would then have won their bet and would have a greatly reduced debt load.

  • Reply to

    cMET as a Prognostic Marker in Gastric Cancer

    by wilderguide Nov 9, 2013 12:23 PM
    conditionstabel conditionstabel Nov 11, 2013 9:31 AM Flag

    We wouldn't want anyone to infer the positive implications of this study, would we? Of course we are all aware that clinical testing will have to be done, but medical history is replete with miraculous drugs that work for one thing but were originally developed for something else.

    The association of clearly worse outcomes with higher cMet in more than one cancer makes Cometriq ( a drug that '"clearly" reduces or eliminates cMet ) a leading candidate to be "the next big thing" in cancer research.

  • Reply to

    cMET as a Prognostic Marker in Gastric Cancer

    by wilderguide Nov 9, 2013 12:23 PM
    conditionstabel conditionstabel Nov 10, 2013 4:53 PM Flag

    From the article: Kind of a layup for Cometriq, don't you think?

    "To our knowledge, this is the first meta-analysis that strongly suggests high c-Met status represent adverse prognostic biomarker for overall survival in GC patients. Patients with tumors that harbour high c-Met expression are more likely to have a worse OS, and this prognostic effect was independent to disease stage. However, large studies using standardized unbiased methods are still required before c-Met testing can move toward routine clinical application as a prognostic tool.

    Collectively, this study’s overall findings support the hypothesis that c-Met expression level is associated with overall survival in GC patients. Future studies should try to block HGF/c-Met pathway so as to prolong the overall survival of GC patients, and the prognosis of patients harbouring high c-Met expression would be changed with more and more clinical trials evaluating targeted agents against HGF or c-Met in GC patients."

  • conditionstabel conditionstabel Oct 28, 2013 6:49 PM Flag

    Whoops, it looks like a Wed Nov 6th release. Sorry about the date error.

    So have you heard any "whisper" numbers?

    The shorts seem to be a little anxious to cover and if we get a similar beat to last quarter we could see a fairly strong short squeeze taking the share price right back up over $20.

    Sentiment: Buy

  • I know this leaves it open for anybody to jump in but I thought we'd see what happens.

3.32+0.10(+3.11%)Apr 16 4:00 PMEDT

Trending Tickers

Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.
Google Inc.
NasdaqGSWed, Apr 16, 2014 4:00 PM EDT
Google Inc.
NasdaqGSWed, Apr 16, 2014 4:00 PM EDT